- Home
- NRXP vs BCLI Comparison
NRXP vs BCLI Comparison
Compare NRXP & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- BCLI
- Stock Information
- Founded
- NRXP 2015
- BCLI 2000
- Country
- NRXP United States
- BCLI United States
- Employees
- NRXP N/A
- BCLI N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRXP Health Care
- BCLI Health Care
- Exchange
- NRXP Nasdaq
- BCLI Nasdaq
- Market Cap
- NRXP 48.5M
- BCLI 13.5M
- IPO Year
- NRXP N/A
- BCLI N/A
- Fundamental
- Price
- NRXP $4.01
- BCLI $1.89
- Analyst Decision
- NRXP Strong Buy
- BCLI Strong Buy
- Analyst Count
- NRXP 3
- BCLI 1
- Target Price
- NRXP $31.67
- BCLI $30.00
- AVG Volume (30 Days)
- NRXP 2.8M
- BCLI 109.6K
- Earning Date
- NRXP 11-14-2024
- BCLI 11-14-2024
- Dividend Yield
- NRXP N/A
- BCLI N/A
- EPS Growth
- NRXP N/A
- BCLI N/A
- EPS
- NRXP N/A
- BCLI N/A
- Revenue
- NRXP N/A
- BCLI N/A
- Revenue This Year
- NRXP N/A
- BCLI N/A
- Revenue Next Year
- NRXP N/A
- BCLI N/A
- P/E Ratio
- NRXP N/A
- BCLI N/A
- Revenue Growth
- NRXP N/A
- BCLI N/A
- 52 Week Low
- NRXP $1.10
- BCLI $1.05
- 52 Week High
- NRXP $7.33
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- NRXP 61.48
- BCLI 44.80
- Support Level
- NRXP $3.20
- BCLI $1.90
- Resistance Level
- NRXP $6.01
- BCLI $2.17
- Average True Range (ATR)
- NRXP 0.95
- BCLI 0.18
- MACD
- NRXP 0.11
- BCLI -0.05
- Stochastic Oscillator
- NRXP 56.52
- BCLI 4.76
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.